An Investigation of Presumptive Synergism of Oil Palm Bunch Ash and Sawdust Amendments in Remediation of crude oil Spiked Soil

Presumed synergistic effect of combined amendment of crude oil spiked soil with oil palm bunch ash and sawdust was carried out in a laboratory experiment. Two kilogram (2 kg) of sandy soil was placed in each of five plastic vessels labeled TA, TB, TC, TD and TE. TA was left in its natural state while the others were each polluted with 6.7% v/w of crude oil. TB was not given any remediation amendment. TC and TD were each amended with 13.3% of oil palm bunch ash and sawdust respectively while TE was amended with 13.3% each of oil palm bunch ash and sawdust. The setups were replicated five times and watered twice weekly. Results showed that soil pH increased from 8.7±0.04 to 10.5±0.06, 5.3±0.01 to 8.5±0.04 and 5.6±0.18 to 11.5±0.15 for TC, TD and TE respectively. Percentage total petroleum hydrocarbon contents reduced by 65% for TC, TD and 52% for TE. Total organic carbon increased from 7.6±0.7 to 8.5±0.5%%, reduced from 4.0±0.1% to 3.7±0.3% and from 4.1±0.1% to 2.2±1.0% TC, TD and TE respectively. Total nitrogen increased from 0.66±0.1 to 0.69±0.0% for TC, remained nearly the same for TD and reduced from 0.4±0.0 to 0.2±0.0% for TE while average phosphorus increased from 0.4±0.0 to 23.0±4.2 mg/kg, 0.3±0.0 to 1.8±0.4 mg/kg and from 0.2±1.0 mg/kg to 52.6±4.6 mg/kg for TC, TD and TE respectively. Conclusively, combined amendment with oil palm bunch ash and sawdust did not induce synergism in soil total petroleum hydrocarbon content reduction.

Analgesic synergism of gabapentin and carbamazepine in rat model of diabetic neuropathic pain

Purpose: To evaluate synergy in the analgesic effects of a combination therapy of carbamazepine (CBZ) and gabapentin (GBP) in diabetic neuropathic pain. Methods: Neuropathic pain was produced in rats by a single intraperitoneal injection of streptozotocin (STZ) at 60 mg/kg. CBZ, GBP, and their combination were orally administered at varying doses (GBP 30 - 180 mg/kg; CBZ 20 - 40 mg/kg) comparable to their therapeutic doses in humans. Nociceptive responses in the diabetic rats were assessed using hot plate test. Results: Hot plate latency significantly increased with oral administration of GBP at a dose of 180 mg/kg when compared with control group (p < 0.05), while at a dose of 90 mg/kg, the increase was not significant. Oral administration of CBZ at doses of 20 and 40 mg/kg did not produce any significant impact on hot plate latency. However, a combination of GBP at 90 mg/kg and CBZ at 20 mg/kg produced significant increase in latency, compared with control group and other groups (p < 0.05), except the group that received 180 mg/kg GBP. The combination of low dose GBP 30 mg/kg and carbamazepine 30 mg/kg had no significant effect on latency (p > 0.05). Conclusion: The results obtained in this study provide useful information on the combination therapy of GBP and CBZ, which may be applied in the treatment of pain in diabetic neuropathy.

Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates

Mycobacterium tuberculosis (Mtb) has acquired resistance and consequently the antibiotic therapeutic options available against this microorganism are limited. In this scenario, the use of usnic acid (UA), a natural compound, encapsulated into liposomes is proposed as a new approach in multidrug-resistant tuberculosis (MDR-TB) therapy. Thus the aim of this study was to evaluate the effect of the encapsulation of UA into liposomes, as well as its combination with antituberculous agents such as rifampicin (RIF) and isoniazid (INH) against MDR-TB clinical isolates. The in vitro antimycobacterial activity of UA-loaded liposomes (UA-Lipo) against MDR-TB was assessed by the microdilution method. The in vitro interaction of UA with antituberculous agents was carried out using checkerboard method. Minimal inhibitory concentration values were 31.25 and 0.98 μg/mL for UA and UA-Lipo, respectively. The results exhibited a synergistic interaction between RIF and UA [fractional inhibitory concentration index (FICI) = 0.31] or UA-Lipo (FICI = 0.28). Regarding INH, the combination of UA or UA-Lipo revealed no marked effect (FICI = 1.30-2.50). The UA-Lipo may be used as a dosage form to improve the antimycobacterial activity of RIF, a first-line drug for the treatment of infections caused by Mtb.